Combinatorial strategies with pd-1/ pd-l1 immune checkpoint blockade for breast cancer therapy: mechanisms and clinical outcomes

HIGHLIGHTS

• who: Dan Zheng et al. from the Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China, Department of Neurosurgery, Hospital of have published the Article: Combinatorial Strategies With PD-1/ PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes, in the Journal: (JOURNAL)
• what: In contrast to the trial of ENHANCE I, the frequency of ORR in this trial demonstrated no significant difference between the pembrolizumab treatment group and the eribulin treatment group in the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.